Our study offers a strong proof-of-principle of repurposing niclosamide as the first HuR inhibitor to test in clinic, to modulate HuR-PD-L1 signaling to improve the response of ICB immunotherapy, especially for the immune “cold” breast cancer. This evidence concerns the gene CD274 and breast carcinoma.